UK Markets close in 1 hr 47 mins

InflaRx N.V. (IFRX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.2292+0.1492 (+13.81%)
As of 09:43AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close1.0800
Bid1.2600 x 3200
Ask1.2700 x 1000
Day's range1.1400 - 1.2500
52-week range0.7760 - 5.6860
Avg. volume192,712
Market cap54.314M
Beta (5Y monthly)0.82
PE ratio (TTM)N/A
EPS (TTM)-1.2570
Earnings date23 Mar 2022 - 28 Mar 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est8.13
  • Globe Newswire

    InflaRx to Present at the H.C. Wainwright Global Investment Conference

    JENA, Germany, May 17, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced that management will give a company presentation at the upcoming H.C. Wainwright Global Investment Conference. The hybrid conference will be held in person in Miami, Florida and virtually from May 23rd to May 26th. InflaRx will present in person on Wednesday, May 25th at 10:30 AM EDT /

  • Globe Newswire

    InflaRx Reports First Quarter 2022 Financial and Operating Results and Provides Strategic Update

    Quarter highlighted by progress with vilobelimab in several indications: Encouraging Phase III topline results reported in patients with severe COVID-19; discussions with regulatory authorities already underwayFinal data from Phase IIa open-label study in patients with pyoderma gangrenosum presented at 2022 AAD Annual Meeting; end-of-Phase II meeting with FDA scheduled for mid-2022In Phase II trial in cutaneous squamous cell carcinoma, second dosing cohort of combination arm started; enrollment

  • Simply Wall St.

    Here's Why We're Not Too Worried About InflaRx's (NASDAQ:IFRX) Cash Burn Situation

    We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...